Schall Law investigates Elicio after Phase 2 trial failure
The Schall Law Firm announced an investigation into Elicio Therapeutics regarding potential securities law violations after the company's Phase 2 AMPLIFY-7P study failed to meet its primary endpoint of disease-free survival. The announcement led to a nearly 71% drop in Elicio's stock price on June 15, 2026. Elicio plans to refine its Phase 3 strategy and initiate a Phase 1 combination study subject to funding.
*this image is generated using AI for illustrative purposes only.
The Schall Law Firm is investigating claims on behalf of investors of Elicio Therapeutics, Inc. regarding potential violations of securities laws. The investigation follows a significant decline in the company's stock price after Elicio announced that its Phase 2 AMPLIFY-7P study failed to meet its primary endpoint. On June 15, 2026, Elicio’s stock price fell by almost 71%, closing at $4.08 per share after dropping $9.97.
The investigation centers on whether Elicio issued false and/or misleading statements and/or failed to disclose information pertinent to investors. This scrutiny arises after the company reported that the AMPLIFY-7P study did not achieve the pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population. Pomerantz LLP is also investigating similar claims regarding potential securities fraud and other unlawful business practices.
Clinical Context
Elicio had previously reported 100% confirmed complete radiographic and complete metabolic responses in three metastatic pancreatic cancer patients who progressed on ELI-002 7P treatment and subsequently received Bristol-Myers Squibb & Co.’s Opdivo (nivolumab)-based therapy. These patients demonstrated persistent mutant KRAS (mKRAS)-specific T cell responses and were microsatellite stable (MSS) / mismatch repair proficient (MMR-p), a population historically less responsive to immune checkpoint inhibitors.
Future Development Plans
Despite the Phase 2 failure, Elicio outlined a refined Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic cancer. Subject to funding, the company plans to initiate a Phase 1 study evaluating ELI-002 7P in combination with standard gemcitabine/nab-paclitaxel chemotherapy and an anti-PD-1 inhibitor in treatment-naïve metastatic mKRAS pancreatic cancer. The company intends to use findings from the AMPLIFY-7P study to evaluate checkpoint inhibitor combinations and inform future development strategies.
| Metric | Detail |
|---|---|
| Stock Price Decline | $9.97 per share (almost 71%) |
| Closing Price (June 15, 2026) | $4.08 per share |
| Primary Endpoint Status | Not met (DFS) |
| Planned Next Step | Phase 1 combination study |
How will the ongoing securities investigations impact Elicio's ability to secure necessary funding for future clinical trials?
What specific biomarkers or patient subsets will Elicio target to differentiate the upcoming Phase 1 combination study from the failed AMPLIFY-7P trial?
Could the failure of the monotherapy approach prompt Elicio to seek strategic partnerships or mergers to sustain operations?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
